title: [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports].
abstract: An increase in the expression of epidermal growth factor receptors (EGFR) is involved in the stimulation of tumor development. EGFR inhibitors have shown efficacy in the treatment of neoplasms of the head, neck, colon and lung. EGFR when inhibited can cause cutaneous reactions in more than 50% of the patients. They are usually reversible, but when severe, limit the use of the drug. Papulopustulars lesions in the face and upper torso are the most common, as well as xerosis, hair and nail changes. There is a direct relationship between the degree of cutaneous toxicity and the antitumoral response. An adequate dermatologic approach is necessary for an effective therapy against cancer.
authors.affiliation: Clínica Médica, Hospital Geral de Goiânia, GO, Brasil. camilamrodarte@hotmail.com
authors.forename: Camila Martins
authors.initials: CM
authors.lastname: Rodarte
authors.forename: Omar Ali
authors.initials: OA
authors.lastname: Abdallah
authors.forename: Nadyesda Fagundes
authors.initials: NF
authors.lastname: Barbosa
authors.forename: Ludmila de Oliveira
authors.initials: Lde O
authors.lastname: Koch
authors.forename: Uirá Maira
authors.initials: UM
authors.lastname: Resende
mesh_terms: D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003875:Drug Eruptions / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068818:Cetuximab